Healthcare AI scribe Suki raises $90 million Series E to expand agentic workflows
Suki secured $90 million in Series E funding led by Healthier Capital to scale its ambient scribe technology and integrate new agentic workflows for healthcare providers.
Key points
- Suki raised $90 million in a Series E funding round.
- Healthier Capital led the investment round.
- The company projects annual revenue between $60 million and $80 million.
Suki, an artificial intelligence company that provides ambient scribe services for healthcare providers, has raised $90 million in a Series E funding round. According to CEO Punit Soni, the capital will be used to scale operations and add agentic workflows to the platform.
Healthier Capital led the investment round, as reported by Axios Pro. The funding announcement was accompanied by financial projections from a source familiar with the company. That source indicated Suki expects to generate between $60 million and $80 million in revenue this year.
Context and background
Suki positions itself as a healthcare AI and scribe company. The new investment comes as the firm seeks to expand its technological capabilities beyond standard transcription. CEO Punit Soni told Axios Pro exclusively that the funds will support the addition of agentic workflows. These workflows are intended to automate more complex tasks within clinical environments.
The Series E round marks a significant step in the company’s growth trajectory. By securing this level of funding, Suki aims to enhance its value proposition for medical professionals. The focus on agentic workflows suggests a move toward more autonomous AI assistance in documentation and patient care coordination.
Who is affected
Healthcare providers using Suki’s ambient scribe technology will see the impact of this investment. The company serves clinicians who require efficient documentation tools to reduce administrative burden. The expansion into agentic workflows may change how these providers interact with AI during patient encounters.
The financial projections indicate a growing user base or increased adoption of existing features. With expected revenue between $60 million and $80 million this year, Suki is scaling its operations to meet demand. Healthcare organizations relying on AI scribes should monitor these developments for potential service updates.
What should you do?
Organizations evaluating or using AI scribe tools should review their vendor’s roadmap. The introduction of agentic workflows may require updates to internal data governance policies. Security teams should assess how new AI features handle sensitive patient information.
What to do and how to stay safe: Suki
- Review vendor documentation to understand how new agentic workflows process and store patient data.
- Evaluate current data privacy controls to ensure they align with expanded AI capabilities.
- Monitor vendor communications for updates on feature rollouts and security enhancements.
- Assess internal training needs for staff adapting to more autonomous AI assistance tools.
Step-by-step guide: Prompt Injection Warning Signs: How to Spot AI Manipulation
General security guidance from the Threat Times newsroom. It is not confirmed advice from the organisations named in this story.
Frequently asked questions
How much funding did Suki raise?
Suki raised $90 million in a Series E funding round.
Who led the investment round?
Healthier Capital led the Series E investment round.
What are Suki’s revenue projections?
A source says Suki projects $60 million to $80 million in revenue this year.
